Tofacitinib

Results: 22



#Item
1------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme

------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2015-06-22 13:44:18
2HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STIVARGA safely and effectively. See full prescribing information for STIVARGA.   Dermatological toxicity: Interr

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STIVARGA safely and effectively. See full prescribing information for STIVARGA.  Dermatological toxicity: Interr

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2015-04-14 15:23:06
3HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use VOTRIENT safely and effectively. See full prescribing information for VOTRIENT.  gastrointestinal perforation or

HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use VOTRIENT safely and effectively. See full prescribing information for VOTRIENT. gastrointestinal perforation or

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2015-04-02 10:46:40
4Tofacitinib for chronic plaque psoriasis – second line

Tofacitinib for chronic plaque psoriasis – second line

Add to Reading List

Source URL: www.hsc.nihr.ac.uk

Language: English
    5542  CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

    542 CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

    Add to Reading List

    Source URL: www.ncbi.nlm.nih.gov

    Language: English
    6s p e c i a l f e at u r e  © John Bavosi / Photo Researchers, Inc. Osteoarthritis and Rheumatoid ­Arthritis 2012:

    s p e c i a l f e at u r e © John Bavosi / Photo Researchers, Inc. Osteoarthritis and Rheumatoid ­Arthritis 2012:

    Add to Reading List

    Source URL: www.nphealthcarefoundation.org

    Language: English - Date: 2012-10-29 11:36:28
    7THE PIPELINE REPORT[removed]PHARMA’S FRONTRUNNERS Profiling a dozen agents on deck

    THE PIPELINE REPORT[removed]PHARMA’S FRONTRUNNERS Profiling a dozen agents on deck

    Add to Reading List

    Source URL: media.mmm-online.com

    Language: English - Date: 2013-05-21 21:35:48
    8Downloaded from http://ard.bmj.com/ on November 25, [removed]Published by group.bmj.com 290 REVIEW  Early referral recommendation for newly diagnosed

    Downloaded from http://ard.bmj.com/ on November 25, [removed]Published by group.bmj.com 290 REVIEW Early referral recommendation for newly diagnosed

    Add to Reading List

    Source URL: ard.bmj.com

    Language: English
    9REMS Initial REMS Approval: [removed]Most Recent Modification: [removed]NDA 203,214 XELJANZ® (TOFACITINIB)

    REMS Initial REMS Approval: [removed]Most Recent Modification: [removed]NDA 203,214 XELJANZ® (TOFACITINIB)

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    10Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

    Microsoft Word - pdl_notice_tesamorelin_tofacitinib_ldo_avis-fra.docx

    Add to Reading List

    Source URL: hc-sc.gc.ca

    Language: French - Date: 2014-05-12 14:23:37